VistaGen Therapeutics Inc Stock News

VistaGen Therapeutics, Inc. (VTGN) CEO Shawn Singh on Q3 2022 Results - Earnings Call Transcript

VistaGen Therapeutics press release (VTGN): Q3 GAAP EPS of -$0.05 beats by $0.02.Revenue of $0.36M (+16.1% Y/Y) beats by $0.11M.At December 31, 2021, the Company had cash and

SOUTH SAN FRANCISCO, Calif., Feb. 10, 2022 (GLOBE NEWSWIRE) --  VistaGen Therapeutics, Inc. (Nasdaq: VTGN), a company developing therapeutics to transform the treatment paradigm for patients suffer

VistaGen Therapeutics (NASDAQ:VTGN) is scheduled to announce Q3 earnings results on Thursday, February 10th, after market close.The consensus EPS Estimate is -$0.07 (flat Y/Y) and…

SOUTH SAN FRANCISCO, Calif., Feb. 07, 2022 (GLOBE NEWSWIRE) -- VistaGen Therapeutics, Inc. (NASDAQ: VTGN), a biopharmaceutical company committed to developing and commercializing innovative medicine

SOUTH SAN FRANCISCO, Calif., Feb. 07, 2022 (GLOBE NEWSWIRE) -- VistaGen Therapeutics, Inc . (NASDAQ: VTGN), a biopharmaceutical company committed to developing and commercializing innovative medicines

VistaGen Therapeutics, Inc. (VTGN) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

VistaGen Therapeutics Inc (VTGN) shares closed today at 0.7% above its 52 week low of $1.53, giving the company a market cap of $307M. The stock is currently down 21.0% year-to-date, down 32.5% over the past 12 months, and down 54.7% over the past five years. This week, the Dow Jones Industrial Average fell 3.8%, and the S&P 500 fell 3.8%. Trading Activity Trading volume this week was 2.8% higher than the 20-day average.Beta, a measure of the stocks volatility relative to the overall market stands at 1.3. Technical Indicators The Relative Strength Index (RSI) on the stock was under 30, indicating it may be underbought.MACD, a trend-following momentum indicator, indicates a downward trend.The stock closed above its Bollinger band, indicating it may be overbought. Market Comparative Performance The company's share price is the same as the S&P 500 Index , lags it on a 1-year basis, and lags it on a 5-year basis The company's share price is the same as the Dow Jones Industrial Average , lags it on a 1-year basis, and lags it on a 5-year basis The company share price is the same as the performance of its peers in the Health Care industry sector , lags it on a 1-year basis, and lags it on a 5 year basis Per Group Comparative Performance The company's stock price performance year-to-date lags the peer average by 572.4% The company's stock price performance over the past 12 months lags the peer average by 235.6% This story was produced by the Kwhen Automated News Generator. For more articles like this, please visit us at finance.kwhen.com. Write to [email protected]. © 2020 Kwhen Inc.

Equities research analysts expect VistaGen Therapeutics, Inc. (NASDAQ:VTGN) to announce $330,000.00 in sales for the current quarter, Zacks reports. Two analysts have made estimates for VistaGen Therapeutics earnings, with estimates ranging from $300,000.00 to $360,000.00. VistaGen Therapeutics reported sales of $310,000.00 during the same quarter last year, which would suggest a positive year over year []

Renaissance Technologies LLC bought a new position in shares of VistaGen Therapeutics, Inc. (NASDAQ:VTGN) in the 2nd quarter, Holdings Channel reports. The fund bought 102,641 shares of the companys stock, valued at approximately $323,000. A number of other institutional investors have also recently made changes to their positions in VTGN. Xponance Inc. bought a new []

State Street Corp acquired a new stake in VistaGen Therapeutics, Inc. (NASDAQ:VTGN) during the second quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor acquired 3,059,610 shares of the companys stock, valued at approximately $9,638,000. State Street Corp owned 1.59% of VistaGen Therapeutics as of []

Nuveen Asset Management LLC acquired a new position in VistaGen Therapeutics, Inc. (NASDAQ:VTGN) in the 2nd quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The fund acquired 686,380 shares of the companys stock, valued at approximately $2,163,000. A number of other institutional investors have also modified their []

Equities analysts expect VistaGen Therapeutics, Inc. (NASDAQ:VTGN) to report sales of $330,000.00 for the current fiscal quarter, Zacks reports. Two analysts have made estimates for VistaGen Therapeutics earnings, with estimates ranging from $300,000.00 to $360,000.00. VistaGen Therapeutics posted sales of $310,000.00 during the same quarter last year, which suggests a positive year over year growth []

SOUTH SAN FRANCISCO, Calif., Nov. 16, 2021 (GLOBE NEWSWIRE) -- VistaGen Therapeutics, Inc . (NASDAQ: VTGN), a biopharmaceutical company committed to developing and commercializing a new generation of medicines with the potential to go beyond the current standard of care for anxiety, depression, and other central nervous system (CNS) disorders, today announced that Shawn Singh, Chief Executive Officer, will participate in a fireside chat with Jefferies analyst, Andrew Tsai as part of the Jefferies Virtual London Healthcare Conference on Thursday, November 18, 2021. Management will be available during the conference for virtual one-on-one meetings.

VistaGen Therapeutics, Inc. (NASDAQ:VTGN) Stock analysts at William Blair reduced their Q3 2022 earnings estimates for VistaGen Therapeutics in a research report issued on Thursday, November 11th. William Blair analyst T. Lugo now forecasts that the company will post earnings of ($0.08) per share for the quarter, down from their prior estimate of ($0.07). []